www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/BioInvent-Registration-of-BioInvent-s-rights-issue-completed-1818000 Regulatory News: The new shares issued by BioInvent International (OMXS:BINV) in connection with the company’s preferential rights issue has been registered by the Swedish Companies Registration Office and ...http://www.finanzen.net/nachricht/BioInvent-Registration-of-BioInvent-s-rights-issue-completed-1818000http://www.finanzen.net/nachricht/Recruitment-of-Patients-Completed-in-Phase-II-Study-with-BI-204-1699812 <style type="text/css"> <!-- .bwuline {text-decoration: underline} --> </style> BioInvent International AB (OMXS: BINV) and its collaborator Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced ...http://www.finanzen.net/nachricht/Recruitment-of-Patients-Completed-in-Phase-II-Study-with-BI-204-1699812http://www.finanzen.net/nachricht/BioInvent-and-Servier-Enter-Oncology-Collaboration-1544965 <style type="text/css"> <!-- .bwuline {text-decoration: underline} --> </style> BioInvent International AB (OMXS: BINV) (Bioinvent) and Les Laboratoires Servier (Servier) have entered into an antibody collaboration on an ...http://www.finanzen.net/nachricht/BioInvent-and-Servier-Enter-Oncology-Collaboration-1544965http://www.finanzen.net/nachricht/ThromboGenics-and-BioInvent-Complete-Enrolment-of-Phase-IIb-Trial-with-TB-402-ahead-of-schedule-1523532 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwuline {text-decoration: underline} --> </style> <!-- sh_cad_1 --> ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: ...http://www.finanzen.net/nachricht/ThromboGenics-and-BioInvent-Complete-Enrolment-of-Phase-IIb-Trial-with-TB-402-ahead-of-schedule-1523532http://www.finanzen.net/nachricht/BioInvent-Anti-Cancer-Activity-of-BI-505-Demonstrated-in-Animal-Model-1514745 <style type="text/css"> <!-- .bwalignl {text-align: left} .bwuline {text-decoration: underline} --> </style> <!-- sh_cad_1 --> BioInvent International AB (OMXS: BINV) announced today that new preclinical data has been presented on ...http://www.finanzen.net/nachricht/BioInvent-Anti-Cancer-Activity-of-BI-505-Demonstrated-in-Animal-Model-1514745http://www.finanzen.net/nachricht/BioInvent-holds-Capital-Markets-Day-in-Stockholm-1461915 <style type="text/css"> <!-- .bwuline {text-decoration: underline} --> </style> BioInvent International AB (STO:BINV) will hold its first Capital Markets Day for investors, analysts and media today. <!-- sh_cad_1 --> ...http://www.finanzen.net/nachricht/BioInvent-holds-Capital-Markets-Day-in-Stockholm-1461915http://www.finanzen.net/nachricht/aktien/Wall-Street-endet-uneinheitlich-DAX-schliesst-mit-deutlichen-Verlusten-Google-ueberrascht-positiv-Slowakei-stimmt-erweitertem-Euro-Rettungsschirm-zu-JPMorgan-Suedzucker-im-Fokus-1413917<b>Termine vom 13.10.11:</b><br> - JP: BoJ Sitzungsprotokoll<br> - D: Verbraucherpreise September<br> - USA: Erstantr&auml;ge Arbeitslosenhilfe<br> - USA: &Ouml;llagerbest&auml;nde<br> - USA: Handelsbilanz August<br> - USA: Staatshaushalt September<br> - ...http://www.finanzen.net/nachricht/aktien/Wall-Street-endet-uneinheitlich-DAX-schliesst-mit-deutlichen-Verlusten-Google-ueberrascht-positiv-Slowakei-stimmt-erweitertem-Euro-Rettungsschirm-zu-JPMorgan-Suedzucker-im-Fokus-1413917http://www.finanzen.net/nachricht/Invitation-to-BioInvent-Capital-Markets-Day-on-November-8-2011-1367014 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwuline {text-decoration: underline} --> </style> <p class="bwalignc"> We have the pleasure to invite participants of the capital market and media to BioInvent’s first ...http://www.finanzen.net/nachricht/Invitation-to-BioInvent-Capital-Markets-Day-on-November-8-2011-1367014http://www.finanzen.net/nachricht/BioInvent-and-ThromboGenics-Announce-the-Start-of-New-Study-of-Novel-Antibody-Anti-Cancer-Agent-TB-403-Anti-PlGF-by-Partner-Roche-1127723 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwuline {text-decoration: underline} --> </style> <!-- sh_cad_1 --> BioInvent International AB (STO:BINV) and co-development partner ThromboGenics NV (Euronext Brussels: ...http://www.finanzen.net/nachricht/BioInvent-and-ThromboGenics-Announce-the-Start-of-New-Study-of-Novel-Antibody-Anti-Cancer-Agent-TB-403-Anti-PlGF-by-Partner-Roche-1127723http://www.finanzen.net/nachricht/EMG-s-Gas-Supply-to-Israel-Interrupted-Due-to-EGAS-Mandatory-Shut-Down-Procedure-after-an-Explosion-in-the-Egyptian-National-Grid-in-the-Sinai-1107097 <style type="text/css"> <!-- .bwalignc {text-align: center} .bwuline {text-decoration: underline} --> </style> <!-- sh_cad_1 --> Ampal-American Israel Corporation (Nasdaq: AMPL), a holding company in the business of acquiring and ...http://www.finanzen.net/nachricht/EMG-s-Gas-Supply-to-Israel-Interrupted-Due-to-EGAS-Mandatory-Shut-Down-Procedure-after-an-Explosion-in-the-Egyptian-National-Grid-in-the-Sinai-1107097